Bemotrizinol US FDA approval spurs sunscreen innovation
Earlier this summer, sunscreen active ingredient bemotrizinol (BEMT) received US FDA approval, marking a major milestone for sunscreen innovation in the country. It became the first new sunscreen active approved in the US in over 25 years.
Single-Cell Striatum Atlas Reveals Neurological Disorder Vulnerabilities
The striatum, a brain region involved in movement, decision-making, habit formation, and reward processing, is also implicated in some of the most difficult-to-treat neurological and psychiatric disorders, including Huntington’s disease, schizophrenia, depression, and substance use disorder. Now, MIT researchers have created a single-cell atlas of the striatum that could help explain why particular neuronal populations are vulnerable in different diseases and potentially point toward more targeted drug strategies.
Lower Ground Beef Import Tariffs Does Little For Australian Beef
September 2026, AU: Independent analyst from Global AgriTrends Simon Quilty outlines the potential implications of Presi…
CD Bioparticles releases exosomes targeting medical aesthetics
CD Bioparticles has launched a product portfolio of exosomes designed for the beauty industry. The lineup is said to help repair skin barriers, reduce signs of aging, lighten hyperpigmentation, and rejuvenate hair follicles, and is positioned as particularly attractive for medical aesthetics and sensitive-skin applications.
🎥 Carbon Robotics: $100m+ revenue, new machine and a path to IPO
Seattle-based Carbon Robotics is aiming to become a publicly traded company as it continues to scale its laser weeding a…
Amyl Tx raises €8.25M to develop universal neurodegeneration drug
Why it matters: Amid a resurgence in venture capital funding for European biotechs, Amyl Tx has raised money to complete key tasks on its path to clinical development. The biotech will use the cash to finalize development of its clinical candidate ready for GMP manufacturing and collect preclinical in vivo efficacy and safety data to validate its platform.
Symrise offloads terpenes business to Mutares in Care & Wellness pivot
Symrise has sold its AmeriTerpenes business to private equity firm Mutares for an undisclosed amount. The move allows the company to focus more on its higher-margin segments, under its One Symrise strategy, and grants Mutares ownership of the terpene-based raw materials business.
Agriculture Production To Ease Slightly
September 2026, AU: ABARES is forecasting the value of agricultural production to fall by 5% to $99.4 billion in 2026-27…
🎥 ‘The whole system is now more investable’: Reservoir makes the case for ag robotics
When growers are testing new ag robots, they will usually tell you one of two things, observed Ben Palone at Western Gro…
Adaptyv raises $40M for AI-run wet labs
Why it matters: AI can already propose thousands of new proteins faster than researchers can experimentally test them. Adaptyv wants to close that gap by building automated labs that AI systems can access directly, eventually allowing agents to design an experiment, receive real-world results and decide what to test next.